Wednesday, June 18, 2025 12:57:47 PM
olekbolek,
When NWBO and long investors are waiting for the price sustaining news of validation, nothing else matters to share price until that news. What needs to be done to get there can’t be sped up by anyone so everyone is left to wait. No one wants to hear they need to wait without a set date so NWBO remains mostly silent.
Sharing their preparations for what is to come does not move the needle as the recent presentations prove. Those saying PRs help share price just got proved wrong and NWBO proved correct that they get attacked. The day of the presentation the price went down so I guess FeMike wasn’t buying in support of the company PR ; ). Some did try to support but that got shot down quickly. We wait, patiently or impatiently, we wait; ). Best wishes.
When NWBO and long investors are waiting for the price sustaining news of validation, nothing else matters to share price until that news. What needs to be done to get there can’t be sped up by anyone so everyone is left to wait. No one wants to hear they need to wait without a set date so NWBO remains mostly silent.
Sharing their preparations for what is to come does not move the needle as the recent presentations prove. Those saying PRs help share price just got proved wrong and NWBO proved correct that they get attacked. The day of the presentation the price went down so I guess FeMike wasn’t buying in support of the company PR ; ). Some did try to support but that got shot down quickly. We wait, patiently or impatiently, we wait; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses • PR Newswire (US) • 07/08/2026 06:42:00 PM
- Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses • PR Newswire (US) • 07/08/2026 06:24:00 PM
- Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting • PR Newswire (US) • 07/02/2026 06:41:00 PM
- Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting • PR Newswire (US) • 07/02/2026 06:17:00 PM
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
